Form 4: CFO Conway Reports GBIO Stock Transactions

Generation Bio Co.'s CFO, Kevin John Conway, reported the acquisition of common stock from restricted stock unit vesting and a subsequent disposition for tax purposes.

Summary

• Kevin John Conway, Chief Financial Officer of Generation Bio Co. (GBIO), reported transactions on January 15, 2026.
• Conway acquired 59 shares of common stock through the vesting and conversion of restricted stock units (RSUs).
• Conway disposed of 17 shares of common stock at a price of $5.64 per share to cover tax withholding obligations related to the RSU vesting.
• Following these transactions, Conway directly beneficially owns 1,909 shares of common stock and 235 restricted stock units.
• The restricted stock units were part of an original grant of 9,390 units made on January 20, 2023, with a vesting schedule over four years, including 25% vested on January 15, 2024, and the remainder vesting in equal quarterly installments thereafter.

Sentiment

Score: 5

Explanation: Neutral. This is a routine insider transaction filing (Form 4) reporting the vesting of restricted stock units and subsequent tax-related disposition, which is a standard compensation event and does not reflect positively or negatively on company performance or outlook.

Positives

• CFO Kevin John Conway acquired 59 shares of Generation Bio Co. common stock through the vesting of restricted stock units, indicating a scheduled equity compensation event.

Negatives

• CFO Kevin John Conway disposed of 17 shares of common stock at $5.64 per share to satisfy tax withholding obligations related to the restricted stock unit vesting, resulting in a reduction of direct share ownership.

Stakeholder Impact

• Shareholders: Provides transparency into executive equity ownership changes, which is standard for compensation disclosures.
• Employees (specifically the CFO): The vesting of restricted stock units represents a realization of previously granted equity compensation.

Next Steps

• Remaining restricted stock units from the January 20, 2023 grant will continue to vest in equal quarterly installments after January 15, 2024.

Key Dates

Keywords

Generation Bio Co., GBIO, Form 4, Insider Trading, Stock Transaction, Restricted Stock Units, CFO, Kevin John Conway, Equity Compensation